Increased Plasma Levels of Pentraxin 3 Are Associated with Poor Prognosis of Colorectal Carcinoma Patients

Abstract

Colorectal carcinoma (CRC) is one of the most common cancers globally. It is essential to identify a prognostic predictor for CRC. Pentraxin 3 (PTX3) is a glycoprotein that is secreted by a variety of human cells. It plays an important role in inflammation and immune regulation. Increasing evidence reveals that elevated PTX3 expression is related to poor prognosis in various cancers. The aim of the study was to determine the usefulness of plasma PTX3 level as a prognostic predictor in CRC. Total 184 CRC patients and 216 controls were included. Plasma levels of PTX3 were determined using Enzyme-linked immunosorbent assays. On admission, plasma PTX3 levels in CRC patients were higher than those in controls (11.8 ± 2.5 ng/ml vs. 3.1 ± 0.9 ng/ml, P < 0.001). After resection, plasma PTX3 levels in patients were decreased (6.0 ± 1.4 ng/ml, P = 0.007), and were elevated at the time of relapse (10.8 ± 2.8 ng/ml, P < 0.001). During the 60-month follow-up period, 108 patients suffered from relapse. Plasma PTX3 levels of ≥ 12 ng/ml on admission were associated with relapse (OR: 3.11, 95% CI: 1.74 ~ 6.29), and tumor-free survival rate in those patients with plasma PTX3 levels of ≥ 12 ng/ml was lower than that in other patients (P = 0.001). Furthermore, plasma PTX3 levels on admission showed positive linear correlations with plasma complement 3, 4 and 5b9 levels (P < 0.001, P < 0.001, P < 0.001). Therefore, we propose that PTX3 is an independent prognostic indicator in CRC.

Increased serum pentraxin-3 level predicts poor prognosis in patients with colorectal cancer after curative surgery, a cohort study

“…Thus, although PTX3 serves as a useful prognostic biomarker for CRC, the optimum cut-off value for the PTX3 may differ in various studies enrolled patients with different stage, or different endpoint and statistics mothed. [ 29 ]…”

The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer

“…In prostate cancer patients, circulating levels of PTX3 were higher compared to patients with prostatic inflammation, while serum levels of prostate-specific antigen (PSA) and CRP were not different between the two groups (134). In CRC, PTX3 circulating levels were significantly increased compared to healthy individuals or to patients with colorectal polyps, representing an independent prognostic factor for CRC patients (135). PTX3 levels were reduced at discharge after surgery, and a subsequent increase during the follow-up was associated to recurrence.…”

<p>Tumor Necrosis Factor Alpha-Induced Proteins in Malignant Tumors: Progress and Prospects</p>

“…69 In addition, Zhang et al found that increased PTX3 was related to the poor prognosis of patients with CRC, and confirmed that PTX3 was an independent prognostic factor for CRC. 70 Carmo et al found that PTX3 polymorphism was associated with the incidence of hepatitis C. The polymorphism of PTX3 rs2305619 and plasma level were associated with liver cancer patients with Child grade B and C, while PTX3 seemed to be a risk factor for patients with liver cancer and chronic hepatitis C. 71 In summary, TNFAIP5 or PTX3 overexpression in tumors might indicate the risk of disease recurrence and metastasis, and it could be a prediction and prognostic factor for patients with malignant tumors.…”